Amicus Therapeutics, Inc.
FOLD
$9.92
$0.141.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 598.70M | 571.16M | 543.14M | 528.30M | 493.67M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 598.70M | 571.16M | 543.14M | 528.30M | 493.67M |
| Cost of Revenue | 61.22M | 55.03M | 51.07M | 52.94M | 49.43M |
| Gross Profit | 537.49M | 516.13M | 492.07M | 475.35M | 444.24M |
| SG&A Expenses | 353.07M | 338.14M | 327.18M | 323.38M | 306.95M |
| Depreciation & Amortization | 7.60M | 7.90M | 8.23M | 8.55M | 8.69M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 564.19M | 546.11M | 495.35M | 494.23M | 479.27M |
| Operating Income | 34.52M | 25.05M | 47.79M | 34.06M | 14.40M |
| Income Before Tax | 4.98M | -22.51M | -3.22M | -28.76M | -68.35M |
| Income Tax Expenses | 19.04M | 15.59M | 26.16M | 27.35M | 36.34M |
| Earnings from Continuing Operations | -14.06 | -38.10 | -29.37 | -56.11 | -104.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.06M | -38.10M | -29.37M | -56.11M | -104.69M |
| EBIT | 34.52M | 25.05M | 47.79M | 34.06M | 14.40M |
| EBITDA | 42.12M | 32.95M | 56.02M | 42.61M | 23.09M |
| EPS Basic | -0.05 | -0.12 | -0.10 | -0.19 | -0.35 |
| Normalized Basic EPS | 0.01 | -0.04 | 0.00 | -0.04 | -0.09 |
| EPS Diluted | -0.05 | -0.12 | -0.10 | -0.19 | -0.35 |
| Normalized Diluted EPS | 0.01 | -0.04 | 0.00 | -0.04 | -0.09 |
| Average Basic Shares Outstanding | 1.23B | 1.23B | 1.22B | 1.22B | 1.21B |
| Average Diluted Shares Outstanding | 1.23B | 1.23B | 1.22B | 1.22B | 1.21B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |